SWAN Genomics
Unlocking the future of genomics with ultra-scalable, affordable, and precise single-molecule sequencing for healthcare and research
Learn More
Spinout
Challenge
• current DNA sequencing technologies( both short-read and long-read) suffer tradeoffs between cost, scalability, accuracy and read length.
• these constraints hinder widespread adoption, prevent population-scale genomics, and slow progress in healthcare and research, leaving critical genetic insights inaccessible or unaffordable for many applications and regions.
Solution
Swan Genomics ' single-molecule sequencing platform overcomes the limitations of existing shortand long-read technologies. It uses proprietary nanoscale optical antennae to amplify the fluorescent signal of a single molecule by 1,000-fold, allowing us to isolate and identify individual nucleotides in real time.
Ultra‐cheap chemical synthesis will allow long- and short-read sequencing at unprecedented scale, accuracy and costefficiency. Swan Genomics enables genomic insights at population scale for better diagnostics, personalised medicine, and biotechnology.
Target customers / end-users
• healthcare
• agriculture
• defence
• biotechnology
Progress
• AUD8 million pre-seed invested from Australia, US and NZ
• partnerships with Fonterra and the Australian Genome Research Facility
• world-class leadership team: 25 + patents, 100 + publications, 300 + products, 15 + companies exited.
Proof-of-concept
TRL 4
Healthy Living
Team with decades of success in commercialising DNA sequencing technologies including in ABI, Illumina, PacBio, and Omniome tackling the AUD100 billion + global genomics market.
100 •